SG166125A1 - New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease - Google Patents

New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease

Info

Publication number
SG166125A1
SG166125A1 SG201007265-0A SG2010072650A SG166125A1 SG 166125 A1 SG166125 A1 SG 166125A1 SG 2010072650 A SG2010072650 A SG 2010072650A SG 166125 A1 SG166125 A1 SG 166125A1
Authority
SG
Singapore
Prior art keywords
pyrimidine derivatives
disease
dementia
treatment
alzheimeræs
Prior art date
Application number
SG201007265-0A
Other languages
English (en)
Inventor
Lars Andersson
Erwan Arzel
Stefan Berg
Jeremy Burrows
Sven Hellberg
Fernando Huerta
Torben Pedersen
Tobias Rein
Didier Rotticci
Karin Staaf
Dominika Turek
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG166125A1 publication Critical patent/SG166125A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG201007265-0A 2005-10-03 2006-10-02 New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease SG166125A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0502174 2005-10-03

Publications (1)

Publication Number Publication Date
SG166125A1 true SG166125A1 (en) 2010-11-29

Family

ID=37906403

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201007265-0A SG166125A1 (en) 2005-10-03 2006-10-02 New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease

Country Status (20)

Country Link
US (1) US20090105252A1 (ru)
EP (1) EP1945628A4 (ru)
JP (1) JP2009513575A (ru)
KR (1) KR20080059423A (ru)
CN (1) CN101326179A (ru)
AR (1) AR058073A1 (ru)
AU (2) AU2006297890B2 (ru)
BR (1) BRPI0616658A2 (ru)
CA (1) CA2624875A1 (ru)
EC (1) ECSP088405A (ru)
IL (1) IL190150A0 (ru)
NO (1) NO20082067L (ru)
NZ (2) NZ566804A (ru)
RU (2) RU2433128C2 (ru)
SG (1) SG166125A1 (ru)
TW (1) TW200800957A (ru)
UA (1) UA92181C2 (ru)
UY (1) UY29827A1 (ru)
WO (1) WO2007040440A1 (ru)
ZA (1) ZA200802897B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
WO2009017455A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
AU2009276699A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
PE20110843A1 (es) 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
CN102459252A (zh) * 2009-04-15 2012-05-16 阿斯利康(瑞典)有限公司 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
CA2763167A1 (en) 2009-06-08 2010-12-16 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
NZ596863A (en) 2009-06-08 2014-02-28 Gilead Sciences Inc Alkanoylamino benzamide aniline hdac inhibitor compounds
WO2012050517A1 (en) * 2010-10-14 2012-04-19 Astrazeneca Ab Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムInserm 神経筋接合部関連疾患の処置方法
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
BR112022018477A2 (pt) * 2020-03-23 2022-11-01 Whan In Pharmaceutical Co Ltd Composto derivado de pirimidina, composição compreendendo o mesmo, e seus usos na prevenção ou tratamento de doenças neurodegenerativas e câncer
KR102342803B1 (ko) * 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
CN114426542B (zh) * 2020-10-29 2023-06-30 苏州亚宝药物研发有限公司 取代的二芳基胺化合物及其药物组合物、制备方法和用途
JP2024517792A (ja) * 2021-04-28 2024-04-23 コーネル・ユニバーシティー 可溶性アデニリルシクラーゼ(sAC)阻害剤及びその使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530710A1 (de) 1985-08-28 1987-03-05 Hoechst Ag Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7078410B2 (en) * 2001-02-20 2006-07-18 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of GSK3-related disorders
SE0100569D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EP1448556A1 (en) * 2001-11-01 2004-08-25 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) * 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
EP1554269A1 (en) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
JP2006518381A (ja) * 2003-02-07 2006-08-10 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
AU2004221881A1 (en) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP1648887A1 (en) * 2003-07-30 2006-04-26 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US7132651B2 (en) 2004-04-23 2006-11-07 Framatome Anp, Inc. In-situ BWR and PWR CRUD flake analysis method and tool
WO2007015064A1 (en) * 2005-07-30 2007-02-08 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
CN102459252A (zh) * 2009-04-15 2012-05-16 阿斯利康(瑞典)有限公司 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶

Also Published As

Publication number Publication date
EP1945628A1 (en) 2008-07-23
RU2008110910A (ru) 2009-11-10
IL190150A0 (en) 2008-08-07
CA2624875A1 (en) 2007-04-12
ECSP088405A (es) 2008-05-30
EP1945628A4 (en) 2010-06-02
AU2006297890A1 (en) 2007-04-12
TW200800957A (en) 2008-01-01
WO2007040440A1 (en) 2007-04-12
KR20080059423A (ko) 2008-06-27
UA92181C2 (ru) 2010-10-11
NZ566804A (en) 2011-03-31
CN101326179A (zh) 2008-12-17
UY29827A1 (es) 2007-05-31
NO20082067L (no) 2008-07-02
ZA200802897B (en) 2008-12-31
AU2011200948A1 (en) 2011-03-24
NZ591316A (en) 2012-06-29
AU2006297890B2 (en) 2011-04-28
US20090105252A1 (en) 2009-04-23
JP2009513575A (ja) 2009-04-02
BRPI0616658A2 (pt) 2011-06-28
AR058073A1 (es) 2008-01-23
RU2011115406A (ru) 2012-10-27
RU2433128C2 (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
SG166125A1 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease
TW200745111A (en) New compounds
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
DE60318193D1 (en) Phenethanolaminderivate
TW200606164A (en) New compounds
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO2008002244A8 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
SG137850A1 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
DE60315492D1 (de) Medizinisch verwendbare arylethanolamin verbindungen
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
MXPA04009163A (es) Nuevos compuestos.
SG157242A1 (en) Medicaments with hm74a receptor agonist activity
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
TW200800984A (en) New compounds
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.